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Molecular Mechanism of MBX2319 Inhibition of Escherichia coli AcrB
Multidrug Efflux Pump and Comparison with Other Inhibitors
Attilio V. Vargiu,a Paolo Ruggerone,a Timothy J. Opperman,b Son T. Nguyen,b Hiroshi Nikaidoc
Department of Physics, University of Cagliari, Monserrato, Cagliari, Italya; Microbiotix, Inc., Worcester, Massachusetts, USAb; Department of Molecular and Cell Biology,
University of California, Berkeley, California, USAc
Efflux pumps of the resistance nodulation division (RND) superfamily, such as AcrB, make a major contribution to multidrug
resistance in Gram-negative bacteria. The development of inhibitors of the RND pumps would improve the efficacy of current
and next-generation antibiotics. To date, however, only one inhibitor has been cocrystallized with AcrB. Thus, in silico struc-
ture-based analysis is essential for elucidating the interaction between other inhibitors and the efflux pumps. In this work, we
used computer docking andmolecular dynamics simulations to study the interaction between AcrB and the compound
MBX2319, a novel pyranopyridine efflux pump inhibitor with potent activity against RND efflux pumps of Enterobacteriaceae
species, as well as other known inhibitors (D13-9001, 1-[1-naphthylmethyl]-piperazine, and phenylalanylarginine--naphthyl-
amide) and the binding of doxorubicin to the efflux-defective F610A variant of AcrB.We also analyzed the binding of a sub-
strate, minocycline, for comparison. Our results show that MBX2319 binds very tightly to the lower part of the distal pocket in
the B protomer of AcrB, strongly interacting with the phenylalanines lining the hydrophobic trap, where the hydrophobic por-
tion of D13-9001 was found to bind by X-ray crystallography. Additionally, MBX2319 binds to AcrB in a manner that is similar
to the way in which doxorubicin binds to the F610A variant of AcrB. In contrast, 1-(1-naphthylmethyl)-piperazine and phenyla-
lanylarginine--naphthylamide appear to bind to somewhat different areas of the distal pocket in the B protomer of AcrB than
does MBX2319. However, all inhibitors (except D13-9001) appear to distort the structure of the distal pocket, impairing the
proper binding of substrates.
In the past 3 decades, there has been a resurgence of bacterialresistance as a major problem in public health (1–3). Of partic-
ular concern is the appearance of multidrug-resistant (MDR)
Gram-negative bacteria (1, 2), in which the efflux pumps of the
resistance nodulation division (RND) family make a major con-
tribution to the MDR phenotype (4–6). The substrates of the RND
family pumps include antibiotics and biocides with very diverse
structural and chemical features; however, they tend to have a
significant lipophilic portion (6, 7). RND pumps are tripartite
complexes (7–9). The major RND efflux system in Escherichia coli
consists of a pump protein (AcrB), a channel that traverses the
outer membrane (TolC), and a membrane fusion (adaptor)
protein (AcrA). The RND pump AcrB, which is driven by pro-
ton motive force (10), determines the substrate specificity (2, 5,
6, 8, 11).
The structure of AcrB, a homotrimeric protein embedded in
the bacterial inner membrane, has been determined in a 3-fold
symmetric form (12) and later in an asymmetric conformation
(13–15). In the asymmetric conformation, each protomer as-
sumes a different conformation: access (loose or A), binding (tight
or B), or extrusion (open or C). Furthermore, minocycline (MIN)
and doxorubicin (DOX) were cocrystallized within a distal (deep)
binding pocket (DP) located in the periplasmic domain of the
binding conformer (13) (Fig. 1). On the basis of these findings, a
functional rotation hypothesis was suggested for the mechanism
of drug efflux, in which each protomer successively assumes one
of the aforementioned conformations (13–15). This idea has been
supported by several biochemical studies (16–18) and by molec-
ular simulation (19, 20). Thus, the DP (Fig. 1) plays a major role in
the binding and selection of substrates by AcrB. Indeed, site-di-
rected mutagenesis and real-time efflux experiments have con-
firmed this hypothesis (21–24). The DP in the binding protomer is
quite extensive (surrounded by20 residues) and contains many
hydrophobic residues, as well as several charged and polar ones
(Fig. 1) (25). The diverse features of the DP are consistent with the
extreme variety of substrates recognized by AcrB (8), ranging
from basic dyes to most antibiotics, detergents, and even solvents
(5, 26, 27). Recently, some antibiotics have been cocrystallized in a
form bound to a more proximal binding pocket (also called the
access pocket [AP]) in the access protomer (28, 29). This presum-
ably represents an earlier stage in the drug efflux process and is
consistent with earlier cocrystallization (30) and biochemical (31)
studies. AP and DP are separated by a loop rich in glycine (G-loop)
(also called F617 loop or switch loop), consisting of residues 614
through 621 (28, 29).
Efflux pump inhibitors (EPIs) (Fig. 2) are of extreme interest in
antimicrobial research, as their use might, in principle, restore the
efficacy of several antibiotics (32–40). Their biological activities,
measured by decreases in antibiotic MICs (Table 1), suggest that
the EPIs studied here (Fig. 2) affect the efflux of many antibiotics,
but there are important differences in specificity that may be re-
lated to the modes of binding of EPI to DP, as is explained in the
Discussion. Several EPIs from various research groups are cur-
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rently under study, but their possible mechanisms of action re-
main largely unknown (32–38). They might compete with sub-
strates for the DP or AP, bind to AcrB partners (e.g., to the access
mouth of TolC, thus interfering with the translocation of sub-
strates), or interfere with the assembly of the AcrB trimer (which
should assemble after insertion and folding of the three mono-
mers in the inner membrane [41]) or the tripartite AcrAB-TolC
machinery.
The first (and so far the only) structure of an inhibitor cocrys-
tallized with an RND efflux pump is that of D13-9001 bound to
AcrB of E. coli and MexB of Pseudomonas aeruginosa, which was
released very recently (42). The inhibitor binds to the DP of the
two transporters, and Nakashima et al. (42) suggested that it com-
petitively inhibits the functional rearrangements of the efflux
pumps at work, sterically preventing the binding and transport of
typical substrates.
As stressed in a previous investigation of the binding of a dozen
compounds to AcrB (25), the availability of a single experimental
structure, although constituting a milestone in the field, does not
allow a comparison with other inhibitors or the identification of a
general mechanism of pump inactivation. Thus, we have utilized
computational methods, such as docking and all-atom molecular
dynamics (MD) simulations, to predict the molecular details of
the interaction between other EPIs and RND transporters (25, 43),
including the binding of 1-(1-naphthylmethyl)-piperazine
(NMP) and phenylalanylarginine--naphthylamide (PAN) to
the DP of AcrB. In this work, we extend this approach in order to
study a novel synthetic inhibitor (MBX2319) (Fig. 2), which is a
potent inhibitor of AcrB and some of its orthologs (44). We per-
formed MD simulations on the complexes of AcrB with
MBX2319, the substrate MIN, and the inhibitor D13-9001, for
which experimental structural data are available (13, 28, 29, 42).
Finally, we discovered that the predicted binding mode of
MBX2319 was very similar to that of DOX in the F610A variant of
AcrB (AcrBF610A) (22, 45, 46), in which DOX export is severely
impaired in spite of its predicted strong binding to the DP. Our
results pinpoint the similarities and differences in the binding of
the four inhibitors and suggest a significant concordance of the
mechanism of inhibition by MBX2319 with that suggested for
D13-9001, as well as with that inducing a reduced efflux of sub-
strates in the F610A variant of AcrB.
MATERIALS AND METHODS
The structures of the bimolecular adducts between the ligands and AcrB
were taken from previous works (25, 42) or obtained by docking using
FIG 1 (A) Reduced model of AcrB used in this work. The transmembrane do-
main (in transparent gray) was cut off from the protein, and only the periplasmic
domain (residues 33 to 335 and 565 to 871 of the intact protein; shown in blue, red,
and gray for access, binding, and extrusion protomer, respectively) was kept. The
substrate MIN (PDB code 4DX5 [29]) is shown in spheres (violet), and the mo-
lecular surface of the residues free to move during the partially restrained MD is
shown in transparent yellow. (B) View (perspective looking to the binding
protomer) of the key regions of AcrB. The periplasmic and transmembrane do-
mains of AcrB are shown in red and gray transparent ribbons, respectively, while
the tip of the G-loop is shown in solid yellow. The residues lining the key regions
(see table in panel C) are shown with colored spheres: orange, red, green, magenta,
pink, and ice blue for the PC1/PC2 entrance cleft, distal pocket, access pocket,
hydrophobic trap, vestibule, and exit gate, respectively. A channel leading from the
cleft or the vestibule to the distal pocket is shown by small violet spheres. (C) Table
identifying the residues shown in panel B. The residues common to the cleft and
the access pocket are italicized, while those shared between the access and distal
pockets are underlined. Residues belonging to the hydrophobic trap are in bold
red type and colored magenta.
FIG 2 Chemical structures of the inhibitors MBX2319, D13-9001, PAN, NMP, and of the AcrB substrates DOX and MIN.
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AutoDock Vina (47). A grid of 30 by 30 by 30 Å centered in the middle of
the DP was used. The MD simulations were performed using the program
NAMD 2.9 (48), starting from the best pose obtained from docking. Fur-
ther details about the protocols for docking, MD simulation, and post-
processing, as well as about the analysis of the data, are described in the
supplemental material.
RESULTS
We organized the results as follows. First we describe, in brief, the
main approximations and limitations of our approach. Next, we
discuss the main features of the binding of MBX2319 to the DP of
AcrB and compare them with the binding of the other inhibitors
and the substrate MIN (13, 25, 29), as well as with that of DOX in
the F610A variant of AcrB (22, 45, 46). Finally, using MIN as a
probe in docking and MD simulations, we describe how the in-
hibitors might affect the binding of substrates to the DP. The
choice of the systems made here allows for a solid comparison of
the molecular mechanisms of inhibition by different molecules.
Table S1 in the supplemental material contains a summary of the
simulations performed in this work. Selected properties of all the
compounds are reported in Table S2 in the supplemental material.
Limitations of our approach. In comparison with docking,
all-atom MD simulations have the main advantage of intrinsically
describing the dynamics of the system under study and the role of
solvents. However, with the inclusion of these additional degrees
of freedom, the number of configurations that should be exam-
ined becomes huge, so that insufficient sampling might become an
issue (49). In addition, one has to consider the inaccuracies in the
model. For instance, inhibitors of AcrB contain weakly acidic or
basic groups whose charge states might be different from the stan-
dard one (in aqueous solvent) in the low dielectric constant envi-
ronment of the binding site; this is not taken into account in our
MD simulation protocol. Similarly, a quantitative comparison
among the affinities of the various compounds is compromised by
the intrinsic limitations of the molecular mechanics/generalized
Born surface area (MM/GBSA) methodology used to estimate
binding free energies (see, e.g., 50) and by the quite large standard
deviations accompanying the calculated values of Gb, the total
free energy of binding (Table 2).
Finally, our system may be incomplete because other accessory
proteins, such as AcrA (8) and AcrZ (51, 52), may be needed for
full activity and thus for the active conformation of AcrB. How-
ever, it is likely that the conformation of the complexes of AcrB
with substrates and inhibitors is only marginally affected by the
presence of accessory proteins.
Binding of MBX2319 to the DP of AcrB. The docking of
MBX2319 to AcrB was performed using the AutoDock Vina (47)
package, as described previously (25). The binding of MBX2319 to
AcrB was further characterized through extensive MD simula-
tions of300 ns in length (see Table S1 in the supplemental ma-
terial), starting from the best docking pose and using a reduced
model of the protein lacking the transmembrane domain (Fig. 1).
This model of AcrB was previously validated (25).
The root mean square deviation (RMSD) of the complex, cal-
culated with respect to the initial conformation obtained by dock-
ing, became stable after 90 ns of MD simulation (see Fig. S1 in
the supplemental material). Moreover, after a few nanoseconds,
the inhibitor moved away from the initial pose toward the AP (Fig.
3) (the displacement of the center of mass was8 Å) and bound
stably in a new position for the last 250 ns of the simulation (seeT
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Fig. S1). In this position, MBX2319 binds with high affinity at a
site that is close to the interface between DP and AP (Table 2) and
appears to be in contact with four out of the five phenylalanine
residues lining the hydrophobic trap (Fig. 4A) (F136, F178, F610,
F615, and F628; Fig. 1). Note that this trap, defined by Nakashima
et al. (42) for the inhibitor D13-9001 bound to the B protomer of
AcrB (Fig. 3), is actually a lower part of the DP identified previ-
ously (13, 31). The pyridine ring of MBX2319 stacks with the ring
of F628 on one side and interacts with F136 on the other, while the
morpholine ring is close to Y327, and the phenylethylthio group is
loosely located in a hydrophobic pocket surrounded by F610,
F628, P326, and Y327 (Fig. 4C). Finally, the upper part of the DP,
closer to the exit gate, shrinks instead of making a deep cleft as in
the ligand-free or MIN-bound B protomer, and this phenomenon
is discussed below. The high affinity of MBX2319 for AcrB (calcu-
latedGb,12.5 kcal/mol; Table 2) is supported by the large value
of the matching between the hydrophobic surfaces of inhibitor
and protein (53) (Table 2, surface matching). This is consistent
with the nature of key residues stabilizing the inhibitor in its
pocket, which are almost exclusively aromatic or aliphatic (Fig. 5;
see also Table S3 in the supplemental material). In accordance
with the results reported by Vargiu and Nikaido (25) and con-
firmed here for NMP, PAN, and MBX2319, the residues of the
DP outside the hydrophobic trap do not contribute significantly
to the solvation free energy (Gsolv) (Table 2). Indeed, in the case
of MBX2319, almost 70% of the Gsolv comes from residues be-
longing to the hydrophobic trap (see Fig. 4A). According to Na-
kashima et al. (42), this trap is not in the main part of the substrate
extrusion channel leading from the PC1/PC2 cleft (or from the
vestibule [15, 54]) to the gate of the TolC docking domain (Fig.
1B). Interestingly, the binding of MBX2319 to AcrB does not
cause a significant perturbation in the overall morphology of the
substrate extrusion channel (Fig. 4A, F, and H; see also Fig. S3 in
the supplemental material), except for a reduction of its radius at
the AP with respect to the value in the transporter free of ligands
(Fig. 4H).
Comparison of the binding of MBX2319 with that of NMP,
PAN, D13-9001, MIN, andDOX in AcrBF610A. In order to con-
TABLE 2 Free energy of binding, H-bonds, and surface matching coefficients for the inhibitors MBX2319, NMP, PAN, and D13-9001, the
substrate MIN, all bound to wild-type AcrB, and the substrate DOX bound to the F610A variant of AcrB
Compound
Calculated binding free energy
H-bond interactions and surface
matchingbGb (kcal/mol)
a
Contribution to Gsolv (%)
DPc
G-loop Interface CleftGb Gsolv TSconf Total Trap
f H-bonds SMTot
d SML
d
MBX2319 12.5 	 6.6 37.7 	 2.8 25.2 	 3.8 31 21 (68) 0 2 4 0 (0) 0.77 (0.77) 0.87 (0.87)
NMP 10.6 	 7.9 26.9 	 3.9 16.3 	 4.0 26 18 (69) 4 1 0 0 (0) 0.82 (0.61) 0.91 (0.67)
PAN 13.4 	 10.8 40.8 	 5.8 27.4 	 5.0 32 17 (53) 2 0 0 5.4 (0) 0.71 (0.44) 0.81 (0.63)
D13-9001 18.2 	 12.3 48.8 	 4.8 30.6 	 7.5 49 30 (61) 1 1 1 5.9 (0) 0.74 (0.71) 0.88 (0.91)
MIN 7.2 	 7.7 29.3 	 4.7 22.1 	 3.0 41 12 (29) 0 0 0 0 (1.2) 0.65 (0.62) 0.82 (0.85)
DOXF610A NC
e 30.0 	 4.5 NC 54 28 (52) 3 (NC) 1 (NC) 0 1.1 (NC) 0.71 (NC) 0.84 (NC)
a The total free energy of binding (Gb) is the sum of the contribution calculated with the MM/GBSA method (Gsolv) and of the conformational entropy of the solute (TSconf).
The contributions to Gb from residues belonging to selected regions are also reported. In the case of the hydrophobic trap, embedded in the DP, the weight of the contribution
from the trap relative to the whole pocket is reported in parentheses.
b Calculated on the conformation of the complex with the lower RMSD from the average extracted from the unbiased MD simulations. SMTot and SML refer to the total and
lipophilic surface matching coefficients, respectively. See the supplemental material for further details.
c The residues within the various regions are listed in Fig. 1.
d Values in parentheses are those for the starting structures.
e NC, not calculated.
f Values in parentheses are the percentages of the binding energy contributed by the hydrophobic trap in relation to that contributed by the entire DP.
FIG 3 (A) Representative position of MBX2319 (in thick sticks colored according to the atom type: red, oxygen; yellow, sulfur; dark blue, nitrogen; cyan, carbon;
nonpolar hydrogens are removed) in the equilibrium phase of the MD simulation, compared to the initial pose from docking (thinner gray sticks). The DP
(transparent red surface) and AP (green surface), the cleft (orange surface), and the tip of the G-loop (gray cartoon) are also shown. The residues that are within
3.5 Å from the ligand are shown as beads (red, green, orange, and yellow for those of distal and access pockets, cleft, and G-loop, respectively). Those shared by
the two pockets are colored blue, while the bigger magenta beads represent residues F136, F178, F610, and F628 of the hydrophobic trap. The residues of the exit
gate (far from the ligand) are shown as gray beads. (B) Closer view of interactions realized by the compound with residues within 3.5 Å in the docking geometry.
(C) Closer view of interactions realized by the compound with residues within 3.5 Å in the final phase of the MD (also, the initial docking pose and conformation
of the G-loop are shown in gray sticks and cartoon, respectively).
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FIG 4 (A to E) Positions of the various ligands used in this study with respect to the hydrophobic trap in protomer B of AcrB, as found in representative average
structures of the complexes from MD simulations. The ligands are shown in thick sticks colored according to the atom type (red, oxygen; yellow, sulfur; dark blue,
nitrogen; cyan, carbon; white, hydrogen), and the side chains of the residues constituting the hydrophobic trap are shown with sticks (thick if the residue is within
3.5 Å of the ligand, thinner otherwise). The rest of the protein is shown with the molecular surface colored in orange, yellow, and ice blue at the PC1/PC2 cleft,
the G-loop tip, and the exit gate, respectively, and white elsewhere. The channels leading to the proximity of the exit gate (see Fig. 1) and passing through the
residues of the DP are also shown in the presence and absence of the ligand, with blue and green transparent surfaces, respectively, while the centers of gravity of
the points defining them are shown with points. The centers of mass of the AP and DP are shown with green and red transparent spheres, respectively. No
contiguous substrate translocation channel was found in the AcrB-PAN complex (and also in AcrBF610A-DOX [see Fig. S2 in the supplemental material]). (A
to E) MBX2319 (A), D13-9001 (B), NMP (C), PAN (D), and MIN(E). (F) Channel found in AcrB free of ligands, again as found in the representative average
structure of the transporter. (G) Superposition among the channels in panels A (black), B (red), C (green), E (magenta), and F (yellow). C-
 atoms of the cleft,
exit gate, and distal and access pockets are shown with orange, ice blue, red, and green beads, respectively. (H) Profile radii of the channels calculated in the
presence of the ligands and shown in panel G. The positions of DP, AP, cleft, and gate on the x axis are approximate.
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sistently compare the behavior of MBX2319 with that of NMP and
PAN (25), we extended the MD simulations of those compounds
within the DP of AcrB to300 ns (see Table S1 in the supplemen-
tal material). In addition, we performed an equally long simula-
tion of the complex between AcrB and the inhibitor D13-9001
(42). Finally, we prolonged the simulation of the AcrB-MIN com-
plex of Vargiu and Nikaido (25) to 300 ns. As a reference, we used
both the available high-resolution X-ray structures of AcrB (15,
29) and a previous 100-ns MD trajectory of the protein free of
ligands (25). Before discussing these results further, we would like
to point out that our computational protocol is able to reproduce
very well the binding of MIN and D13-9001 to AcrB, as seen in the
available crystallographic structures (RMSD, 2.7 	 1.0 Å and
2.8 	 0.4 Å from the compounds in the X-ray structures 4DX5
[29] and 3W9H [42], respectively (see Fig. S1 in the supplemental
material).
First, we compared the binding position of MBX2319 with that
of the other inhibitors, as well as with that of DOX in AcrBF610A
(Fig. 6). The largest overlap is seen between MBX2319 and the
region of D13-9001 containing the pyridopyrimidine rings and
the t-butylthiazole moiety (Fig. 6A) that occupy the hydrophobic
trap in the X-ray structure (42) and in our simulation. According
to our data, the conformation of the G-loop is very similar in
these two systems, as well as for the AcrBF610A-DOX complex
(Fig. 6D). The binding sites of NMP and PAN partially over-
lap with that of MBX2319 within the pocket of protomer B, but
to a lesser extent than with D13-9001. Note that only NMP and
PAN straddle the tip of the G-loop (Fig. 4B and C).
While MBX2319 is almost totally packed by the residues lining
the hydrophobic trap, a large portion of D13-9001 extends into
the channel (42) that in the absence of ligands leads from the
PC1/PC2 cleft to the gate of the TolC docking domain passing
through the AP and DP (Fig. 4A and B). This behavior of D13-
9001 is similar to that of DOX in AcrBF610A (see Fig. S2 in the
supplemental material), as evidenced by the good superposition
of these two molecules in the complexes they form with AcrB (see
Fig. S4 in the supplemental material). However, in AcrBF610A,
DOX extends out of the trap much closer to the cleft than does
D13-9001 (the occluding arm of which is in the upper region of
the DP), and no functional channel was found at all. Namely, no
contiguous substrate translocation channels starting from the
PC1/PC2 cleft and leading to the gate through the AP and DP were
found. Several other nonfunctional channels, leading to other re-
gions of the protein or to the cleft through other routes, were
found in all systems.
NMP and PAN affect to a larger extent the morphology of the
substrate extrusion channel, with PAN completely occluding the
passageway (Fig. 4G and H). The position of the bottleneck in
AcrB-NMP, which is closer to the AP than the other inhibitors,
and the total occlusion caused by PAN might be explained by
considering that: (i) these compounds bind to the hydrophobic
trap more peripherally than does MBX2319 (see also in Table 2 the
lower contributions to Gb from this region for these two inhib-
itors compared to the others), and (ii) they significantly drag (and
thus might prevent the movement of) the tip of the G-loop (Fig.
6), which is suggested to act as a gate for the passage of substrates
from the AP to the DP along the A-to-B transition of the func-
tional rotation (28, 29). MBX2319 is unique in this respect among
the inhibitors considered here, as it does not significantly affect the
morphology of the substrate extrusion channel when bound to
AcrB (Fig. 4H). Importantly, the features of the channels de-
FIG 5 Comparison of per-residue contributions to Gb for the inhibitors MBX2319, NMP, PAN, and D13-9001, the substrate MIN, and the substrate DOX
in the F610A variant of AcrB. Residues contributing more than kT (where k is the Boltzmann constant and T is the absolute temperature) at room temperature
(0.593 kcal/mol) for a compound are indicated by colored cells (red, inhibitors and DOX; green, MIN). Cells with semitransparent colors and gray labels identify
residues contributing to Gb for one compound only, while cells with solid colors identify residues contributing to Gb for at least two molecules. The residues
contributing to the binding of two or more inhibitors are in bold type, and those contributing to binding of all inhibitors are also italicized. The residues belonging
to the hydrophobic trap, as defined by Nakashima et al. (42), are underlined, and the corresponding row is shaded gray.
FIG6 Superposition among representative structures of AcrB in complex with MBX2319 (gray sticks in all panels), D13-9001 (A) (red), NMP (B) (green), PAN
(C) (yellow), DOX in complex with AcrBF610A (D) (violet), and MIN (E) (magenta). The G-loop tip is shown in ribbons (gray in free AcrB and colored like the
ligands in complexes), while the residues of the hydrophobic trap within 3.5 Å of the ligands are shown by solid spheres. The two residues of the gate to the TolC
docking domain (Q124 and Y758) are shown by blue spheres.
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scribed above were retained over the MD trajectories of all the
systems studied here (see Fig. S3 in the supplemental material).
To compare the binding affinities of the EPIs and MIN for
AcrB, we estimated their free energies of binding (Gb) from our
MD simulations using the MM/GBSA approach (25, 55–58) (Ta-
ble 2). It is striking to notice (despite the limitations outlined in
“Limitations of our approach” above; note that we did not esti-
mate the entropy contribution to Gb for the AcrBF610A-DOX
system, as we have not extended the simulation of Vargiu et al.
[46] to an acceptable length [25]) that all the inhibitors have bind-
ing free energies in the range of 10 to 18 kcal/mol, with only
the noninhibitor MIN featuring a smaller value of about7 kcal/
mol. Based on theGb values, D13-9001 is predicted to bind with
the highest affinity; however, MBX2319 and DOX in AcrBF610A are
also predicted to bind with high affinity. NMP and PAN exhib-
ited slightly lower Gb values. The finding is consistent with the
differences described above regarding the structure and dynamics
of the inhibitors versus those of MIN.
The contributions from the residues of the hydrophobic trap,
PC1/PC2 cleft, AP/DP interface, and G-loop were all negligible
only for MIN (Table 2). Previously, we highlighted how the con-
tributions to Gb from the residues of DP were approximately
40% for the substrates of AcrB only, while the inhibitors NMP
and PAN had values of30% (25). This result is confirmed here
for MBX2319 but not for D13-9001, which features a contribution
to Gb from residues of the DP that are much higher than the
value of 30% found for the other inhibitors and even higher
than that found for MIN (Table 2). It should be noted that since
this inhibitor is significantly bigger than all the others considered
here (see Table S1 in the supplemental material), it is perhaps not
surprising that the surface contact with the DP is the largest.
Moreover, if one focuses on the contributions from the residues of
the hydrophobic trap, it clearly appears that only for the inhibitors
and DOX in the F610A variant are the values 50% of the total
contribution from the DP, and they drop to 30% for MIN. As
expected, NMP and PAN feature the highest contributions from
the residues of the G-loop.
These results are consistent with the binding positions of
MBX2319 and D13-9001, which are as tightly packed by the hy-
drophobic trap as is DOX in the F610A variant of AcrB (Fig. 4A to
E; see also Fig. S2 and S4 in the supplemental material). As dis-
cussed before, NMP and PAN are only partially bound within
the hydrophobic trap and basically are found between this sub-
pocket and the tip of the G-loop, which they straddle significantly
compared to MBX2319 and D13-9001 (Fig. 6). Concerning MIN,
this substrate binds to the upper portion of the DP, almost totally
outside the hydrophobic trap (Fig. 4E), and it does not contact the
tip of the G-loop (Fig. 6E). Consistently, the contributions to the
Gb from the residues of the trap and the G-loop are the lowest for
MIN (Table 2).
The similarity between the binding of MBX2319 and that of
D13-9001 and DOX in AcrBF610A is strengthened by the observa-
tion of the large overlap between the sets of residues contributing
to the stability of the complexes (Fig. 5). Out of 10 residues con-
tributing to the binding of MBX2319, eight and six residues also
contribute to the stabilization of D13-9001 and DOX, respectively
(Fig. 5; see also Table S3 in the supplemental material). This num-
ber is reduced to three for NMP and PAN and to only one (F178)
for MIN. Furthermore, half of the residues shared with D13-9001
and DOX and all those shared with NMP and PAN belong to the
hydrophobic trap. More in detail, four out of the five residues
lining the hydrophobic trap contribute significantly to the binding
of each inhibitor and DOX, with F136, F178, and F628 contribut-
ing to the binding of all of them (Fig. 5; see also Table S3).
Docking ofMIN to AcrB-inhibitor complexes. To investigate
how the structural deformations of DP induced by inhibitors
might affect the binding of substrates, MIN was docked to the DP
of the B protomer using the representative average structures of
AcrB-inhibitor complexes obtained from the final equilibrium
phases of the MD simulations. As a test, we first docked MIN to
the AcrB-MIN complex after removal of the ligand; MIN was
found to bind to virtually the same position previously occupied
in the MD-simulation complex as well as in the cocrystal structure
(Fig. 7A). However, when MIN was docked on the AcrB-inhibitor
complexes, in all cases, it bound to an area outside the DP proper
(Fig. 7B to E) in a manner that was similar to the manner in which
the nonsubstrates glucose and kanamycin A were predicted to
bind to AcrB in our previous MD simulation study (25). These
results were confirmed by docking MIN on the representatives of
the top 5 structural clusters extracted from the equilibrium trajec-
tories of each of the AcrB-inhibitor systems. Moreover, the con-
formations of the complexes were stable after four consecutive
rounds of structural optimization (see supplemental material for
details). This failure to bind to DP might explain, in principle, how
the inhibitor might work. In examining the structure of the DP in
various complexes (Fig. 7), one is struck by the observation that
MBX2319, NMP, and PAN cause a conformational change that
closes the upper part of the DP, i.e., the portion that appears as a
deep crevice that binds many substrates, including MIN (13, 20,
25, 29, 43). The distances between C- of F178 on the left wall of
this crevice and C- of I277 on the right wall, which was 8.5	 0.5
Å in the MIN-AcrB complex, were found to decrease to 6.6	 0.5
Å for MBX, 6.6	 0.5 Å for NMP, and 6.6	 0.4 Å for PAN in the
inhibitor complexes. This reduction is enough to close the crevice
in the DP and possibly prevents the DP binding of MIN (Fig. 7).
This distance does not decrease in the D13-9001 complex (10.5	
0.5 Å), but MIN presumably cannot bind because the crevice is
occluded by the long tail of the inhibitor containing both positive
and negative charges. Similarly, in the DOXF610A mutant complex,
the distance does not change (8.5 	 0.3 Å), but DOX again pre-
vents the binding of a second substrate by steric hindrance.
DISCUSSION
In this work, we compared the binding features of four different
inhibitors, including the novel potent inhibitor MBX2319, as well
as two substrates of the RND efflux pump AcrB ofE. coli, by means
of computational modeling. The inhibition of this pump and its
homologs is highly desirable in view of combined therapies with
antibiotics (6, 32–35, 44, 59–62). Since AcrB is able to expel per-
haps the largest variety of substrates among the transporters of the
RND superfamily, the importance of understanding the molecu-
lar mechanism behind the inhibition and the differences between
inhibitors and substrates with atomic-level detail cannot be over-
emphasized (3, 5, 6, 63). In recent years, we have performed sev-
eral investigations addressing the functional mechanisms of AcrB
and MexB, the homologue of AcrB in P. aeruginosa, as well as the
reasons for impaired efflux by selected mutations and inhibitors
(see references 20, 25, 46, 58, 64, and 65; reviewed in reference 6),
and in 2013, the first X-ray structure of AcrB in complex with the
inhibitor D13-9001 was released (42). However, to our knowl-
Vargiu et al.
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edge, a thorough and consistent comparison of the binding fea-
tures of several inhibitors has never been published. The impor-
tance of such a study can be understood simply by examining the
molecular properties of the various inhibitors considered here,
which are diverse in terms of molecular weight, flexibility, charge,
H-bond patterns, and octanol-water partition coefficients (see
Table S1 in the supplemental material).
The first notable result of our study is that all inhibitors com-
peted very efficiently with MIN (and likely with other substrates)
in binding to AcrB. Indeed, although the standard deviations ac-
companying the Gb calculations preclude a quantitative discus-
sion of affinity, all inhibitors were found to have higher affinities
for the DP of protomer B than did MIN (Table 2), corresponding
to dissociation constants well below the M range. Moreover, all
but D13-9001 caused a closure of the crevice where MIN has been
found to bind (by crystallography and by MD simulations [13, 25,
29, 43]). Thus, this (competitive) binding of the inhibitors might
alter the properties of the MIN binding site, reducing the affinity
of this and other substrates to the DP of AcrB. D13-9001 extends
from the hydrophobic trap to the MIN binding crevice, which is
thus open in the AcrB-D13-9001 complex. Nonetheless, the much
higher affinity of this inhibitor than that of MIN to the DP points
to a very efficient competitive inhibition mechanism. Irrespective
of the details, the net effect is that the binding of MIN to the DP
becomes impossible (Fig. 7). In the simplest interpretation, this
might explain how all these EPIs work. However, the above hy-
pothesis is likely an oversimplification. This is suggested by the
close analysis of the biological activities of these compounds. Ta-
ble 1 shows that out of 9 compounds for which the reduction in
the MIC was evaluated for MBX2319 and in the F610A variant of
AcrB, 7 (oxacillin [OXA], erythromycin [ERY], linezolid [LZD],
ethidium bromide [EtBr], levofloxacin [LVX], chloramphenicol
[CHL], and tetracycline [TET]) showed comparable values. Sim-
ilarly, ERY and ciprofloxacin (CIP), the only two compounds for
which data are available for both MBX2319 and D13-9001 (44,
66), show approximately the same decreases in MIC. Although
these comparisons might be flawed by the fact that different E. coli
strains were used in other studies (22, 44, 66), the correlation
between the MICs and the structural features of MBX2319, D13-
9001, and DOX binding seems remarkable. Thus, it seems possible
that these inhibitors and the F610A mutation might also block or
retard further conformational changes in the pump, as was pro-
posed earlier for the mutant (46). In this respect, it is interesting to
notice that MBX2319 is almost completely “hidden” within the
hydrophobic trap of protomer B. As this region undergoes large
conformational changes during the functional rotation of AcrB,
the binding of MBX2319 with high affinity might hinder these
rearrangements (or those triggering the translocation of protons
from the periplasm to the cytoplasm upon substrate binding).
Indeed, the binding of MBX2319 resembles that of DOX in
AcrBF610A (Fig. 6; see also Fig. S2 and S4 and Table S3 in the
supplemental material).
In contrast to D13-9001 and DOX in AcrBF610A, the binding
features of PAN and NMP overlap to a lesser extent with those of
MBX2319. In particular, these compounds feature a weaker inter-
action with the hydrophobic trap (Fig. 4 and 5; see also Table S3 in
the supplemental material), partly compensated by a small stabi-
lization from the tip of the G-loop (Table 2), which PAN and
NMP straddle significantly with respect to the conformation in
AcrB free of ligands (Fig. 6). Perhaps these different binding po-
sitions of MBX2319 and PAN are consistent with the different
spectra of compounds potentiated by the two inhibitors (44). In-
deed, ERY, piperacillin (PIP), norfloxacin (NOR), and cloxacillin
(CLO) behaved in a markedly different manner in a study carried
FIG 7 Top docking poses of MIN on representative structures AcrB extracted from the AcrB-MIN MD trajectory (A) and AcrB-inhibitor complex extracted
from the corresponding MD trajectories (B to E). The docked MIN and the inhibitors are shown as sticks colored according to the atom type (white carbons,
MIN; yellow carbons, inhibitors). The green sticks represent the molecule of MIN as found in the highest resolution X-ray structure available to date (29). The
residues of the hydrophobic trap, distal pocket, and PC1/PC2 entrance cleft are shown with magenta, red, and orange spheres, respectively. Residues F136, V139,
F178, I277, A279, E280, P285, Y327, F610, V612, F615, F617, I626, and F628 are rendered with semitransparent surfaces colored according to the atom type
(white carbons). The rest of the protein is shown in gray ribbons.
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out in the same laboratory with the same strain of E. coli (44)
(Table 1). However, as pointed out by Opperman et al. (44), ad-
ditional factors, such as the increase of the outer membrane per-
meability by PAN (61), might also be the reason for this differ-
ence. This argument is weakened in a comparison of the activities
of MBX2319 and NMP, as these compounds are not suspected to
alter the permeability of the outer membrane. In this case, two
drugs (LZD and LVX) behaved very differently among the five
compounds that can be compared (Table 1).
In summary, the observations above suggest that the hypothe-
sis based on the closure of the DP can be only the first approxima-
tion, and there are probably subtle differences in the ways various
EPIs inhibit AcrB function. Ideally, our conclusions based on sim-
ulations should be confirmed by experimental results, such as the
isolation of inhibitor-insensitive mutants, or the chemical modi-
fication of residues suspected in inhibitor binding. Unfortunately,
efforts to isolate mutants resistant to MBX2319 have not been
successful.
Although we have considered only MIN among the substrates
of AcrB, our main findings are confirmed by the analysis of the
complex between the wild-type AcrB and DOX, the only other
substrate of the pump for which binding to the DP of the B
protomer has been established by X-ray crystallography (29). Like
MIN, DOX is also not buried within the hydrophobic trap, being
in contact (within 4 Å) with residues F178 and F615 only (see Fig.
S5 in the supplemental material) and thus susceptible to the same
impairment in binding by the inhibitors considered here.
In summary, all the inhibitors appear to hinder the binding of
substrates to the upper part of the DP, where MIN, a good sub-
strate of AcrB, is bound, by reducing the space available or by
blocking access to this region (Fig. 6 and 7), although there are
likely to be small differences in the way each EPI acts. Obviously, it
is worth pointing out that our discussion has been focused on the
binding of substrates and inhibitors to the DP of AcrB, while other
binding spots not considered here (for instance, the AP in
protomer A) or other factors (such as binding to protein partners)
might play a relevant role in the inhibition of the transporter.
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